<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127679">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809275</url>
  </required_header>
  <id_info>
    <org_study_id>QBECO-01</org_study_id>
    <nct_id>NCT01809275</nct_id>
  </id_info>
  <brief_title>Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease</brief_title>
  <official_title>A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qu Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qu Biologics Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile and to obtain an indication as
      to the therapeutic effect of QBECO induction treatment on clinical improvement in moderate
      to severe Crohn's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessing adverse events, concomitant therapies, clinical chemistry, hematology, urinalysis chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing the change in fecal calprotectin from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing the change in C-reactive protein (CRP) from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>QBECO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QBECO</intervention_name>
    <arm_group_label>QBECO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An adult, age 18 and above

          -  Diagnosed with Crohn's disease AT LEAST six (6) months prior to screening

          -  Crohn's disease diagnosis was verified by one of these procedures: 1) Colonoscopy 2)
             Capsule endoscopy 3) Computed Tomography (CT) scan 4) Magnetic Resonance Imaging
             (MRI) 5) Ultrasound

          -  Active Crohn's disease at the time of screening

          -  Female participants: Agree to practice two effective methods of contraception, at the
             same time, from the time of signing the informed consent form, during the entire
             study treatment and for two (2) months after taking the last dose of study treatment.

          -  Male participants: Agree to practice effective barrier contraception during the
             entire study treatment period and for two (2) months after taking the last dose of
             study treatment.

        Exclusion Criteria:

          -  Currently pregnant or breastfeeding

          -  Have known or suspected hypersensitivity to any component of the product

          -  Had more than three (3) small bowel resections or diagnosis of short bowel syndrome

          -  Currently anticipate undergoing any major surgical intervention for Crohn's disease
             during the next six (6) months

          -  Previously been treated with any Qu Biologics' Site Specific Immunomodulators (SSIs)
             for any disease

          -  Diagnosed with chronic (i.e., long term) hepatitis B or C infection

          -  Diagnosed with congenital (i.e., existing at or before birth) or acquired
             immunodeficiency (i.e., lack of body defense system). For example, human
             immunodeficiency virus (HIV) infection, organ transplantation (i.e., specifically
             received an organ from a donor), etc.

          -  Daily use of narcotic drugs containing opiates (such as morphine, codeine, etc.) for
             pain control

          -  Have a current or recent history (within the past 12 months) of alcohol dependence or
             illicit drug use, with the exception of medicinal marijuana prescribed by a physician

          -  Have a history of cancer within the last five (5) years. Exceptions may apply for
             cervical cancer and some forms of skin cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Bressler, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastrointestinal Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Sutcliffe, MD, FRCP, FRCPC, FRCR</last_name>
    <role>Study Director</role>
    <affiliation>Qu Biologics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winnie Lim</last_name>
    <phone>6047341450</phone>
    <email>qucrohnstrial@qubiologics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrointestinal Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Luna-Algoso</last_name>
      <phone>6046886332</phone>
      <phone_ext>288</phone_ext>
    </contact>
    <investigator>
      <last_name>Brian Bressler, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.qucrohnstrial.com</url>
    <description>Informational website for this trial</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>CDAI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
